文 献 5）Drenberg CD, Paugh SW, Pounds SB, Shi L, Orwick SJ, Li L, et al. Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clin Pharmacol Ther 2016; 99: 651-60. 6）Bhatla D, Gerbing RB, AlonzoTA, Conner H, Ross JA, Meshinchi S, et al. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Haematol 2009; 144: 388-94. 7）Amaki J, Onizuka M, Ohmachi K, Aoyama Y, Hara R, Ichiki A, et al. Single nucleotide polymorphisms of cytarabine metabolic genes influence clin ical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy. Int J Hematol 2015; 101: 543-53. 1）Rasche M, Zimmermann M, Borschel L, Bourquin JP, Dworzak M, Klingebiel T, et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia 2018; 32: 2167-77. 2）Aoki T, Takahashi H, Tanaka S, Shiba N, Hasegawa D, Iwamoto S, et al. Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study. Br J Haematol 2021; 193: 176-80. 3）Elsayed AH, Cao X, Crews KR, Gandhi V, Plunkett W, Rubnitz JE, et al. Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. Pharmacogenomics 2018; 19: 1101-10. 4）Elsayed AH, Cao X, Mitra AK, Wu H, Raimondi S, Cogle C, et al. Polygenic Ara-C response score identifies pediatric patients with acute myeloid leukemia in need of chemotherapy augmentation J Clin Oncol 2022; 40: 772-83.小児急性骨髄性白血病治療において予後に寄与する薬剤代謝動態関連一塩基多型の探索259
元のページ ../index.html#277